This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Avi Kapoor 1 day ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsDowngrades
Analysts downgraded SWK, SHLS, TSN, IDA and ACRS, with mixed price-target changes; ACRS saw the steepest cut, from $8 to $3.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- Mizuho analyst Brett Linzey downgraded Stanley Black & Decker, Inc. (NYSE:SWK) from Outperform to Neutral and raised the price target from $105 to $120. Stanley Black & Decker closed at $112.92 on Monday. See how other analysts view this stock.
- UBS analyst Jon Windham downgraded Shoals Technologies Group, Inc. (NASDAQ:SHLS) from Buy to Neutral and slashed the price target from $12 to $9. Shoals Technologies shares closed at $8.02 on Monday. See how other analysts view this stock.
- JP Morgan analyst Thomas Palmer downgraded Tyson Foods, Inc. (NYSE:TSN) from Overweight to Neutral and raised the price target from $63 to $65. Tyson Foods closed at $63.95 on Monday. See how other analysts view this stock.
- Jefferies analyst Julien Dumoulin-Smith downgraded IDACORP, Inc. (NYSE:IDA) from Buy to Hold and lifted the price target from $155 to $163. Idacorp shares closed at $146.25 on Monday. See how other analysts view this stock.
- Wedbush analyst Martin Fan downgraded Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from Outperform to Neutral and cut the price target from $8 to $3. Aclaris Therapeutics closed at $3.6050 on Monday. See how other analysts view this stock.
Considering buying ACRS stock? Here’s what analysts think:

Photo via Shutterstock
